The Controversies Surrounding Tocilizumab Administration Following Pathogen-Associated Molecular Pattern (PAMP) Induced by COVID-19

Journal of Pharmaceutical Care

Farhad Najmeddin¹  Mojtaba Mojtahedzadeh¹  Bita Shahrami¹  Kourosh Sadeghi¹  Shayesteh Gheibi¹ 

[1] Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.;

关键词: Tocilizumab;    Betacoronavirus;    Coronavirus Infections;    COVID-19;    Pathogen-Associated Molecular Pattern;   

DOI  :  10.18502/jpc.v8i3.4549

来源: DOAJ

【 摘 要 】

A new corona virus disease (COVID-19) is affected more than 5 million people worldwide to date and has become a global pandemic. Since there is no definitive cure for this life threatening disease, many clinical studies are underway in this regard. Pathogen-associated molecular patterns (PAMP) prompting by coronavirus seems to generate cellular, structural, and functional derangement induced by immune dysregulation and many biological abnormalities including cytokine storm. The role of IL-6 in viral pneumonia and also the impact of its inhibition on the prevention of organ damage are not known yet.IL-6 seems to behave as a double blade evil cytokine, with a valuable role in cell to cell natural physiological communication. Tocilizumab as an inhibitor of interleukin (IL)-6, may interrupt the paracrine system while causing dissemination of bacterial, fungal, and other viral infections, especially COVID-19, who are at high-risk development of sepsis and life-threatening superinfection.

【 授权许可】

Unknown